A sarcoma is a type of cancer that develops from certain tissues, such as bone or muscle. There are 2 main types of sarcoma: osteosarcoma, which develops from bone, and soft tissue sarcomas. Soft tissue sarcomas can develop from soft tissues such as fat, muscle, nerves, fibrous tissues, blood vessels, or deep skin tissues. They can be found in any part of the body. Most of them develop in the arms or legs. They can also be found in the trunk, head and neck area, internal organs, and the area in back of the abdominal cavity (known as the retroperitoneum). Sarcomas are not common tumors, and most cancers are the type of tumors called carcinomas.
Treatments for childhood cancer are often intense and carry the risk of lifelong health problems for survivors. An analysis of 23,600 childhood cancer survivors in the Childhood Cancer Survivor Study (CCSS), funded by the National Institutes of Health, found that the rate of severe health problems occurring five or more years after diagnosis has declined over time.
The critical component of an experimental vaccine led to an escalating immune response in patients with sarcoma, an indicator of its potential anti-cancer effects.
Second cancers in children and adolescents and young adults are far deadlier than they are in older adults and may partially account for the relatively poor outcomes of cancer patients ages 15-39 overall, a new study by UC Davis researchers has found.
A very rare sub-type of Non-Hodgkin's Lymphoma, Waldenström's Macroglobulinemia affects approximately 1,500 - 2,000 people in the United States each year. While it is not curable, Waldenström's Macroglobulinemia is slow growing, and in many patients, manageable as a chronic disease.
A drug that's commonly used to treat high blood pressure is being repurposed for a rare tissue cancer in Europe. The medication, named propranolol, was recently granted Orphan Drug Designation by the European Commission.
The National Comprehensive Cancer Network has published the NCCN Guidelines for Patients and NCCN Quick Guide sheets for Brain Cancer - Gliomas—the first in a series of patient education resources focused on Brain Cancer.
The first data on rare sarcomas in Asian patients is presented in three studies today at the ESMO Asia 2016 Congress in Singapore.
The ESMO Asia 2016 Congress announces its press programme today. The meeting brings together cancer experts in Singapore, from 16 to 19 December 2016.
The U.S. Food and Drug Administration today granted accelerated approval to Lartruvo (olaratumab) with doxorubicin to treat adults with certain types of soft tissue sarcoma (STS), which are cancers that develop in muscles, fat, tendons or other soft tissues.
This year, it is estimated that more than 26,000 people will be diagnosed with Stomach Cancer in the United States, with nearly one million new cases diagnosed worldwide each year.
The Sarcoma research group of Bellvitge Biomedical Research Institute, led by Dr. Òscar Martínez-Tirado, has developed a modified version of an orthotopic model that allows researchers to recreate more closely the metastatic steps in Ewing sarcoma (ES), the second most common bone tumor in children and adolescents.
Cancer cells need oxygen to survive, as do most other life forms, but scientists had never tracked their search for oxygen in their early growth stages until now -- a step toward a deeper understanding of one way cancer spreads that could help treat the disease.
Adding a novel monoclonal antibody therapy to traditional chemotherapy increased median survival by nearly a year in patients with advanced sarcoma, a lethal soft-tissue cancer.
Scientists at Duke Health are part of a team that has discovered a type of cell surrounding blood vessels can also serve as a starting point for sarcoma, a form of cancer that occurs in bones and connective tissues.
Mycosis Fungoides is a very rare form of lymphoma affecting approximately 1,000 people per year in the United States.
An existing cancer immunotherapy drug reduces tumor size in some types of rare connective tissue cancers, called sarcomas, report researchers at the University of Pittsburgh Cancer Institute.
It is estimated that more than 72,000 people in the United States will be diagnosed with Non-Hodgkin's Lymphomas (NHL) in 2016. The sixth leading cancer diagnosis in U.S. men and women, NHL has more than 30 sub-types, each featuring unique treatment choices and challenges.
The creation of a network of centres of reference and adopting measures that promote research and access to treatments are two key aspects for improving the prognosis of patients with soft tissue sarcoma (STS), an uncommon type of cancer that originates in the tissues that connect, support and surround other body structures, such as muscles, fat, blood vessels, nerves, tendons and lining of the joints.
Eisai Inc. announced today that the U.S. Food and Drug Administration approved Halaven (eribulin mesylate) Injection (0.5 mg per mL) for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.
The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate), a type of chemotherapy, for the treatment of liposarcoma (a specific type of soft tissue sarcoma) that cannot be removed by surgery (unresectable) or is advanced (metastatic). This treatment is approved for patients who received prior chemotherapy that contained an anthracycline drug.